|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACADVL |
Gene summary for ACADVL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACADVL | Gene ID | 37 |
| Gene name | acyl-CoA dehydrogenase very long chain | |
| Gene Alias | ACAD6 | |
| Cytomap | 17p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | P49748 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 37 | ACADVL | GSM4909281 | Human | Breast | IDC | 1.48e-14 | -5.38e-01 | 0.21 |
| 37 | ACADVL | GSM4909282 | Human | Breast | IDC | 6.91e-27 | -6.48e-01 | -0.0288 |
| 37 | ACADVL | GSM4909285 | Human | Breast | IDC | 2.82e-11 | -4.31e-01 | 0.21 |
| 37 | ACADVL | GSM4909286 | Human | Breast | IDC | 8.44e-34 | -7.11e-01 | 0.1081 |
| 37 | ACADVL | GSM4909287 | Human | Breast | IDC | 1.15e-21 | -6.15e-01 | 0.2057 |
| 37 | ACADVL | GSM4909288 | Human | Breast | IDC | 7.28e-08 | -6.27e-01 | 0.0988 |
| 37 | ACADVL | GSM4909290 | Human | Breast | IDC | 9.24e-20 | -6.51e-01 | 0.2096 |
| 37 | ACADVL | GSM4909291 | Human | Breast | IDC | 8.17e-13 | -6.02e-01 | 0.1753 |
| 37 | ACADVL | GSM4909293 | Human | Breast | IDC | 6.07e-17 | -5.43e-01 | 0.1581 |
| 37 | ACADVL | GSM4909294 | Human | Breast | IDC | 1.27e-26 | -6.72e-01 | 0.2022 |
| 37 | ACADVL | GSM4909295 | Human | Breast | IDC | 7.96e-05 | -4.69e-01 | 0.0898 |
| 37 | ACADVL | GSM4909296 | Human | Breast | IDC | 1.63e-38 | -7.32e-01 | 0.1524 |
| 37 | ACADVL | GSM4909297 | Human | Breast | IDC | 9.42e-22 | -3.12e-01 | 0.1517 |
| 37 | ACADVL | GSM4909298 | Human | Breast | IDC | 6.95e-08 | -3.59e-01 | 0.1551 |
| 37 | ACADVL | GSM4909301 | Human | Breast | IDC | 1.11e-20 | -6.29e-01 | 0.1577 |
| 37 | ACADVL | GSM4909302 | Human | Breast | IDC | 6.60e-07 | -3.80e-01 | 0.1545 |
| 37 | ACADVL | GSM4909307 | Human | Breast | IDC | 3.13e-22 | -6.49e-01 | 0.1569 |
| 37 | ACADVL | GSM4909308 | Human | Breast | IDC | 2.92e-15 | -5.10e-01 | 0.158 |
| 37 | ACADVL | GSM4909309 | Human | Breast | IDC | 2.25e-13 | -5.02e-01 | 0.0483 |
| 37 | ACADVL | GSM4909311 | Human | Breast | IDC | 5.38e-47 | -6.40e-01 | 0.1534 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00094095 | Stomach | SIM | response to cold | 8/708 | 49/18723 | 4.59e-04 | 7.62e-03 | 8 |
| GO:001604211 | Stomach | SIM | lipid catabolic process | 25/708 | 320/18723 | 5.21e-04 | 8.27e-03 | 25 |
| GO:000606611 | Stomach | SIM | alcohol metabolic process | 25/708 | 353/18723 | 2.07e-03 | 2.22e-02 | 25 |
| GO:0019218 | Stomach | SIM | regulation of steroid metabolic process | 10/708 | 100/18723 | 4.55e-03 | 3.97e-02 | 10 |
| GO:00082021 | Stomach | SIM | steroid metabolic process | 22/708 | 319/18723 | 5.09e-03 | 4.32e-02 | 22 |
| GO:001939521 | Stomach | SIM | fatty acid oxidation | 10/708 | 103/18723 | 5.61e-03 | 4.61e-02 | 10 |
| GO:0006091112 | Thyroid | PTC | generation of precursor metabolites and energy | 252/5968 | 490/18723 | 8.24e-20 | 1.13e-17 | 252 |
| GO:0015980111 | Thyroid | PTC | energy derivation by oxidation of organic compounds | 176/5968 | 318/18723 | 2.67e-18 | 2.90e-16 | 176 |
| GO:0009266111 | Thyroid | PTC | response to temperature stimulus | 81/5968 | 178/18723 | 9.20e-05 | 7.63e-04 | 81 |
| GO:001598028 | Thyroid | goiters | energy derivation by oxidation of organic compounds | 43/497 | 318/18723 | 1.21e-18 | 8.38e-16 | 43 |
| GO:000609128 | Thyroid | goiters | generation of precursor metabolites and energy | 48/497 | 490/18723 | 5.54e-15 | 1.53e-12 | 48 |
| GO:000926624 | Thyroid | goiters | response to temperature stimulus | 15/497 | 178/18723 | 8.40e-05 | 2.74e-03 | 15 |
| GO:000940914 | Thyroid | goiters | response to cold | 6/497 | 49/18723 | 1.80e-03 | 3.19e-02 | 6 |
| GO:000609134 | Thyroid | ATC | generation of precursor metabolites and energy | 256/6293 | 490/18723 | 6.55e-18 | 7.69e-16 | 256 |
| GO:001598034 | Thyroid | ATC | energy derivation by oxidation of organic compounds | 177/6293 | 318/18723 | 3.60e-16 | 2.92e-14 | 177 |
| GO:000926632 | Thyroid | ATC | response to temperature stimulus | 83/6293 | 178/18723 | 2.03e-04 | 1.35e-03 | 83 |
| GO:00193959 | Thyroid | ATC | fatty acid oxidation | 46/6293 | 103/18723 | 1.26e-02 | 4.42e-02 | 46 |
| GO:000165912 | Thyroid | ATC | temperature homeostasis | 73/6293 | 174/18723 | 1.29e-02 | 4.51e-02 | 73 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00071 | Colorectum | AD | Fatty acid degradation | 20/2092 | 43/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 20 |
| hsa000711 | Colorectum | AD | Fatty acid degradation | 20/2092 | 43/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 20 |
| hsa000712 | Colorectum | SER | Fatty acid degradation | 15/1580 | 43/8465 | 8.60e-03 | 4.26e-02 | 3.09e-02 | 15 |
| hsa000713 | Colorectum | SER | Fatty acid degradation | 15/1580 | 43/8465 | 8.60e-03 | 4.26e-02 | 3.09e-02 | 15 |
| hsa000714 | Colorectum | MSS | Fatty acid degradation | 17/1875 | 43/8465 | 7.50e-03 | 2.86e-02 | 1.75e-02 | 17 |
| hsa000715 | Colorectum | MSS | Fatty acid degradation | 17/1875 | 43/8465 | 7.50e-03 | 2.86e-02 | 1.75e-02 | 17 |
| hsa000716 | Colorectum | FAP | Fatty acid degradation | 15/1404 | 43/8465 | 2.73e-03 | 1.23e-02 | 7.50e-03 | 15 |
| hsa000717 | Colorectum | FAP | Fatty acid degradation | 15/1404 | 43/8465 | 2.73e-03 | 1.23e-02 | 7.50e-03 | 15 |
| hsa012129 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
| hsa0121214 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
| hsa0007121 | Liver | Cirrhotic | Fatty acid degradation | 29/2530 | 43/8465 | 3.87e-07 | 4.95e-06 | 3.05e-06 | 29 |
| hsa012122 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
| hsa04936 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
| hsa0007131 | Liver | Cirrhotic | Fatty acid degradation | 29/2530 | 43/8465 | 3.87e-07 | 4.95e-06 | 3.05e-06 | 29 |
| hsa012123 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
| hsa049361 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
| hsa012124 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
| hsa0007141 | Liver | HCC | Fatty acid degradation | 33/4020 | 43/8465 | 8.41e-05 | 4.27e-04 | 2.37e-04 | 33 |
| hsa049362 | Liver | HCC | Alcoholic liver disease | 89/4020 | 142/8465 | 1.73e-04 | 8.53e-04 | 4.75e-04 | 89 |
| hsa012125 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACADVL | SNV | Missense_Mutation | c.232N>T | p.His78Tyr | p.H78Y | P49748 | protein_coding | tolerated(1) | benign(0.093) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD | |
| ACADVL | SNV | Missense_Mutation | rs794727111 | c.1435C>T | p.Arg479Cys | p.R479C | P49748 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ACADVL | SNV | Missense_Mutation | c.874G>C | p.Asp292His | p.D292H | P49748 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| ACADVL | SNV | Missense_Mutation | rs762653370 | c.1021N>T | p.Pro341Ser | p.P341S | P49748 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ACADVL | SNV | Missense_Mutation | novel | c.1619N>A | p.Ser540Asn | p.S540N | P49748 | protein_coding | tolerated(0.23) | benign(0.014) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ACADVL | SNV | Missense_Mutation | c.1937N>G | p.Ser646Cys | p.S646C | P49748 | protein_coding | deleterious(0.03) | benign(0.056) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ACADVL | SNV | Missense_Mutation | novel | c.28N>A | p.Gly10Arg | p.G10R | P49748 | protein_coding | tolerated_low_confidence(0.75) | unknown(0) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACADVL | SNV | Missense_Mutation | c.778T>C | p.Cys260Arg | p.C260R | P49748 | protein_coding | deleterious(0.04) | possibly_damaging(0.89) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ACADVL | SNV | Missense_Mutation | c.673N>A | p.Leu225Ile | p.L225I | P49748 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ACADVL | deletion | Frame_Shift_Del | novel | c.1450_1451delNN | p.Phe484Ter | p.F484* | P49748 | protein_coding | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |